SPECIAL ISSUE: LUNG CANCER IN ELDERLY PATIENTS - Locally advanced disease in elderly patients: applicability of Pacific study and future perspectives
L. Ghilardi, A.C. Bettini
Vol.7 (2022), issue 1, pag. 22 - 29
SPECIAL ISSUE: LUNG CANCER IN ELDERLY PATIENTS - Locally advanced disease in elderly patients: applicability of Pacific study and future perspectives
L. Ghilardi, A.C. Bettini
Vol.7 (2022), issue 1, pag. 22 - 29
| Received | 21/09/2021 |
| Accepted | 7/12/2021 |
| Published | 18/01/2022 |
| Review by | Double-blind |
| DOI | https://doi.org/10.48253/AGO21 |
ABSTRACT
Older patients represent a relevant part of non-small cell lung can- cer (NSCLC) population in routine clinical practice, but they are still underrepresented in clinical trials and only a few studies are de- signed speci cally for this age group.
The PACIFIC study demonstrated that the addition of durvalumab in unresectable stage III NSCLC after de nitive chemoradiation (CRT) signi cantly improves PFS and OS, becoming standard of care (SoC) in this disease setting.
Little is known about ef cacy and safety of durvalumab after CRT in frail and older patient.
In this paper weanalyze applicability of this new SoC in the older population and evaluate the future scenario.